Rob Glik brings deep consulting expertise to pharmaceutical and biotech companies by helping them with a wide range of issues including pricing & reimbursement, product strategy, market access, and public policy.

Rob has led multiple projects throughout his consulting career, covering such topics as the Medicare Modernization Act, pricing & reimbursement, market analysis & forecasting, commercialization and out/in-licensing strategies, growth opportunities, new product introductions, and therapeutic area strategies.

Rob joined the Pricing and Reimbursement practice of IMS Consulting (formerly Cambridge Pharma Consultancy) after having led his own strategy consulting firm.  Prior to that, Glik gained pharma/biotech consulting experience at Arthur D. Little and Accenture.  With over a decade of consulting experience, Rob’s record of accomplishment covers many facets of the pharmaceutical, biotechnology and medical device industries.

Rob holds a B.A. in Economics from Columbia University and an M.B.A. in General Management from The Tuck Business School at Dartmouth College. He has also written articles for pharmaceutical trade journals, been quoted in trade publications, and presented at various conferences on topics such as Medicare, Oncology, Drug Pricing, and the Future of the Pharmaceutical Industry.